TET2 was first suspected to have a role in cancer when six patients with either secondary AML (sAML) or MDS were noted to have minimal deletions via FISH on chromosome 4q24 (Viguie et al., 2005). This evidence concerns the gene TET2 and myelodysplastic syndrome.